Disposition of L-732,531, a potent immunosuppressant, in rats and baboons

Drug Metabolism and Disposition

Volumn 26, Issue 10, 1998, Pages 949-957

  Karanam, B V ^b   Miller, R R ^b   Colletti, A ^b   Montgomery, T ^b   Carey, K D ^b   Hawkins, T ^b   Tang, Y S ^b   Lavin, M ^b   Stearns, R A ^b   Chiu, S H L ^b   Vincent, S H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

32 O [1 (2 HYDROXYETHYL) 5 INDOLYL]ASCOMYCIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AREA UNDER CURVE; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOENZYMES; MALE; MICROSOMES, LIVER; PAPIO; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; TISSUE DISTRIBUTION;

ANIMALIA; PAPIO; PAPIO HAMADRYAS; STAPHYLOCOCCUS PHAGE 3A;

EID: 0031785062     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Beysens AJ, Wijnen RMH, Beuman GH, van der Heyden J, Koostra G, and van As H (1991) FK 506: Monitoring in plasma or in whole blood. Transplant Proc. 23:2745-2747.
2. Chen TS, Arison BH, Wicker LS and Inamine ES (1992) Microbial transformation of immuno-suppressive compounds. II. Specific desmethylation of 13-methoxy group of FK506 and FR900520 by Actinomycete sp. ATCC 53828. J Antibiot 45:577-580.
3. Christians U, Kruse C, Kownalzki R, Schiebel HM, Schwinzer R, Sattler M, Schottmann R, Linck A, Almedia VMF and Sewing K-F (1991) Measurement of FK506 by HPLC and isolation and characterization of its metabolites. Transplant Proc 23:940-941.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharmacol Res 10:1093-1095.
5. Dumont FJ, S Koprak, Staruch MJ, Talento A, Koo G, Dasilva C, Sinclair PJ, Wong F, Woods J, Barker J, Pivnichny J, Singer I, Sigal NH, Williamson AR, Parsons WH and Wyvratt M (1998) A macrolimus-related immunosuppressant with reduced toxicity. Transplantation 65:18-26.
6. Feierman DE and Cederbaum AI (1989) Role of cytochrome P450 IIE1 and catalase in the oxidation of acetonitrile to cyanide. Chem Res Toxicol 2:359-366.
7. Guengerich FP (1990) Mechanism-based inactivation of liver microsomal cytochrome P450 IIIA4 by gestodene. Chem Res Toxicol 3:363-371.
8. Guengerich FP and Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol 4:391-407.
9. Kay JE, Sampare-Kwateng E, Geraghty F and Morgan GY (1991) Uptake of FK506 by lymphocytes and erythrocytes. Transplant Proc 23:2760-2762.
10. Legg B and Rowland M (1988) Saturable binding of cyclosporin A to erythrocytes: Estimation of binding parameters in renal transplant patients and implications for bioavailability assessment. Pharm Res 5:80-85.
11. Lin JH (1995) Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23:1008-1021.
12. Machida M, Takahara S, Ishibashi M, Hayashi M, Seikhara T, and Yamanaka H (1991) Effect of temperature and hematocrit on plasma concentration of FK506. Transplant Proc 23:2753-2754.
13. Maurice M, Richard L, Daujat M, Fabre I, Joyeux H, Domerague J and Maurel P (1992) Effects of imidazole derivatives on cytochromeP450 from human hepatocytes in primary culture. FASEB J 6:752-758.
14. Nagase K, Iwasaki K, Nozaki K and Noda K (1994) Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 46:113-117.
15. Nishikawa T, Hasumi H, Suzuki S, Kubo H and Ohtani H (1993) Kinetic analysis of molecular interconversion of immunosuppressant FK506 by high-performance liquid chromatography. Pharm Res 10:1785-1789.
16. Ohara K, Billington R, James RW, Dean GA, Nishiyama M and Noguchi H (1990) Toxicologic evaluation of FK506. Transplant Proc 22:83-86.
17. Pessayre DV, Descatoire V, Konstantinova-Mitcheva M, Wandscheer JC, Cobert B, Level R, Jaouen JP, Mansuy D (1981) Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P450. Biochem Pharmacol 30:553-558.
18. Peterson LB, Cryan JG, Rosa R, Martin MM, Wilusz MB, Sinclair PJ, Wong F, Parsons JN, O'Keefe SJ, Parsons WH, Wyvratt M, Sigal NH, Williamson AR and Wiederrecht GJ (1998) A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. Transplantation 65:10-18.
19. Piekoszewski W, Chow FS and Jusko WJ (1993) Disposition of tacrolimus (FK506) in rabbits: role of red blood cell binding in hepatic clearance. Drug Metab Dispos 21:690-698.
20. Pond SM and Tozer TN (1984) First-pass elimination: basic concepts and clinical consequences. Clin Pharmacokinet 9:1-25.
21. Sarkar M, Polk RE, Guzelian PS, Hunt C and Karnes HT (1990) In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob Agents Chemother 34:594-599.
22. Sinclair PJ, Wong F, Staruch MJ, Wiederrecht G, Parsons WH, Dumont F, Wyvratt M (1996) Preparation and in vitro activity of indolyl ether derivatives of the FK-506 related immunosuppressive macrolide ascomycin. Bioorg Med Chem Lett 6:2193-2198.
23. Vincent SH and Karanam BV (1996) Distribution of FK 506 in human, baboon, rhesus monkey and rat blood is related to the presence and amount of FKBP-12 in erythrocytes. ISSX Proc 10:Abstr 312.
24. Vincent SH, Karanam BV, Painter SK and Chiu SHL (1992) In vitro metabolism of FK506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 2:454-460.
25. Winkler M, Ringe B, Baumann J, Loss M, Wonigeit M, Pichlmayr K (1994) Plasma vs. whole blood for therapeutic monitoring of patients receiving FK506 for immunosuppression. Clin Chem 40:2247-2253.
26. Yeh KC, Winchell GA and Barrett JS (1987) A program for calculating AUC in pharmacokinetics using stable piecewise cubic polynomia linterpolants. J Pharm Sci 76:S104.
27. Zanger UM, Vilbois F, Hardwick JP and Meyer UM (1988) Absence of hepatic cytochrome P450 bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27:5447-5454.